820
Participants
Start Date
December 31, 2006
Primary Completion Date
September 30, 2009
Study Completion Date
July 31, 2011
Aliskiren
Aliskiren was available in 75 mg tablet, 150 mg tablet
placebo
Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
Novartis de Venezuela, S.A., Caracas
Novartis Healthcare Private Limited, Worli, Mumbai
Novartis US, Novartis US
Novartis Argentina, Novartis Argentina
Novartis Belgium, Novartis Belgium
Novartis Canada, Novartis Canada
Novartis de Colombia S.A., Bogotá
Novartis Denmark, Novartis Denmark
Novartis Germany, Novartis Germany
Novartis Italy, Novartis Italy
Novartis Netherlands, Novartis Netherlands
Novartis Norway, Novartis Norway
Novartis Russia, Novartis Russia
Novartis Spain, Novartis Spain
Novartis Sweden, Novartis Sweden
Novartis UK, Novartis
Novartis Czech Republic, Prague
Novartis Hungary, Budapest
Novartis Pharma, Petah Tikva
Novartis Poland Sp. z o.o., Warsaw
Novartis Slovakia, Bratislava
Novartis Korea Ltd., Seoul
Novartis Turkey, Istanbul
Lead Sponsor
Novartis
INDUSTRY